Phase 2: testing Tirzepatide for Central Centrifugal Cicatricial Alopecia (CCCA)
The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are: * Does tirzepatide improve the symptoms and signs of active CCCA?
Official registry: https://clinicaltrials.gov/study/NCT07734870 · Johns Hopkins University · enrollment listed as 20
What this phase means
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Tirzepatide. The registry lists allocation as na. The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults.
They plan to enroll about 20 people at 2 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Tirzepatide for Treatment of CCCA
Interventions: Tirzepatide
Primary outcome (registry wording): Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score
Who it is for (from inclusion criteria)
- Ages 18 Years to 80 Years
- Age 18 to 80 years
- Clinical and/or biopsy-confirmed diagnosis of central centrifugal cicatricial alopecia (CCCA)
- Active CCCA, defined as a C-CAT disease activity score greater than 1
- No treatment for CCCA during the 6 weeks before enrollment
- Able and willing to complete the study and follow all study procedures
- Managed by a Johns Hopkins dermatologist throughout the study
Who the registry excludes
- Currently taking an oral or systemic blood glucose-lowering medication
- Currently taking another medication for weight loss
- Hemoglobin A1C below 5.4%
- Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score below 2
- Body mass index below 19 kg/m²
- Pregnant, breastfeeding, or planning a pregnancy
- Personal or family history of medullary thyroid cancer
Public study contact (from the registry)
Dakarai A Dunbar, BS
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
2 listed- Johns Hopkins Outpatient Center — Baltimore, Maryland (recruiting)
- Medical Pavilion at Howard County — Columbia, Maryland (recruiting)
FAQ about this NCT record
Is NCT07734870 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07734870?
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07734870?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary